Neurotrophic Keratitis Treatment Market Report 2026

The neurotrophic keratitis treatment market size has grown exponentially in recent years. It will grow from $1.47 billion in 2025 to $1.99 billion in 2026 at a compound annual growth rate (CAGR) of 36.1%. The growth in the historic period can be attributed to increasing prevalence of diabetes-related corneal disorders, rising incidence of herpes simplex eye infections, growth in ophthalmology specialty clinics, improved awareness of neurotrophic keratitis among clinicians, expansion of hospital-based eye care services.

The neurotrophic keratitis treatment market size is expected to see exponential growth in the next few years. It will grow to $6.78 billion in 2030 at a compound annual growth rate (CAGR) of 35.8%. The growth in the forecast period can be attributed to advancements in regenerative ophthalmic therapies, increasing approvals of rhNGF-based drugs, growing aging population with nerve degeneration risks, rising investment in rare eye disease research, expanding access to advanced eye care in emerging markets. Major trends in the forecast period include rising adoption of recombinant human nerve growth factor therapies, growing preference for minimally invasive corneal repair procedures, increased focus on early-stage diagnosis and intervention, expansion of homecare-based ophthalmic treatment solutions, advancements in amniotic membrane preservation techniques.

The increasing prevalence of eye diseases is expected to drive the growth of the neurotrophic keratitis treatment market in the coming years. Eye diseases encompass a broad spectrum of conditions that affect the structure and function of the eyes, often resulting in reduced vision or blindness. The rising incidence of eye disorders is attributed to factors such as an aging population, lifestyle changes, and the growing burden of chronic diseases such as diabetes. Neurotrophic keratitis treatment plays a critical role in supporting ocular health by enhancing corneal sensitivity, promoting tissue healing, preventing infections, and reducing pain. For example, in August 2023, according to the World Health Organization (WHO), a Switzerland-based United Nations agency, global estimates revealed that approximately 2.2 billion people suffer from near or distance vision impairment, including 1 billion cases that are preventable or untreated. Refractive errors and cataracts remain the leading causes of vision loss worldwide, and only 36% of individuals with distance impairment due to refractive errors and just 17% of those with cataract-related impairment have received appropriate treatment. Consequently, the growing burden of eye diseases is contributing to the expansion of the neurotrophic keratitis treatment market.

Major companies operating in the neurotrophic keratitis market are concentrating on the development of advanced gene-therapy approaches, including redosable eye-drop therapies, to enhance corneal healing, sustain nerve growth factor (NGF) expression, and lessen the overall treatment burden for patients. Redosable gene-therapy eye drops involve delivering genes that encode NGF directly to the cornea, allowing continuous NGF production and supporting long-term nerve regeneration. For instance, in July 2025, Krystal Biotech, a U.S.-based biotechnology company, announced that the first patient had been dosed in its Phase 1/2 EMERALD 1 study, a randomized, double-masked, placebo-controlled trial enrolling up to 27 adults with stage 2 or 3 neurotrophic keratitis. Administered twice weekly for eight weeks, KB801 is designed to safely promote corneal healing while significantly reducing the treatment burden compared to existing recombinant NGF eye drops that require dosing up to six times per day.

In October 2025, EyeDura Therapeutics, a U.S.-based developer of sustained-release ophthalmic therapies, entered into a strategic research collaboration with the Singapore Eye Research Institute to accelerate the preclinical development of its insulin-based topical therapy for neurotrophic keratitis. Through this collaboration, EyeDura aims to strengthen its technological capabilities and speed up clinical readiness by leveraging SERI’s specialized ophthalmic research infrastructure and preclinical disease models. The Singapore Eye Research Institute is a Singapore-based organization that provides advanced ophthalmic research services, translational science expertise, and preclinical evaluation platforms focused on anterior eye diseases.

Major companies operating in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Johnson & Johnson, Allergan Inc, Alcon Inc, Bausch Health Companies Inc, Bausch & Lomb Inc, CooperVision Inc, Santen Pharmaceutical Co Ltd, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc, Laboratoires Thea SAS, ReGenTree LLC, Contacare Ophthalmic Private Limited, Neuroptika Inc, Surgitech Innovation Private Limited, Aerie Pharmaceuticals Inc, RegeneRx Biopharmaceuticals Inc, Noveome Biotherapeutics Inc, Oyster Point Pharma, Claris Biotherapeutics, Recordati Rare Diseases, Mitotech SA, Kala Pharmaceuticals, Oxurion NV.

North America was the largest region in the neurotrophic keratitis treatment market in 2025. The regions covered in the neurotrophic keratitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurotrophic keratitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the neurotrophic keratitis treatment market by increasing costs of imported biologics, surgical equipment, and specialized ophthalmic devices used in advanced treatments such as rhNGF therapies and keratoplasty. These impacts are most pronounced in hospital and specialty clinic segments and in regions dependent on cross-border pharmaceutical supply chains, particularly in asia-pacific and parts of europe. Higher tariffs have led manufacturers to reassess sourcing strategies and optimize supply chains. On the positive side, tariffs are encouraging local manufacturing and domestic production of ophthalmic drugs and devices, supporting long-term market resilience.

The neurotrophic keratitis treatment market research report is one of a series of new reports that provides neurotrophic keratitis treatment market statistics, including neurotrophic keratitis treatment industry global market size, regional shares, competitors with a neurotrophic keratitis treatment market share, detailed neurotrophic keratitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neurotrophic keratitis treatment industry. This neurotrophic keratitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurotrophic keratitis treatment refers to therapeutic approaches used to manage a rare eye disorder caused by damage to the trigeminal nerve, resulting in reduced corneal sensitivity and a risk of corneal injury. These treatments aim to protect the cornea, support healing, relieve symptoms, and prevent additional damage.

The primary types of neurotrophic keratitis treatment include topical antibiotics, recombinant human nerve growth factor (rhNGF), amniotic membrane transplantation, keratoplasty, and others. Topical antibiotics are antimicrobial drugs applied directly to the surface of the skin or mucous membranes. These treatments are administered through various routes, such as oral, topical, and others, for multiple applications including stage I, stage II, and stage III neurotrophic keratitis, and are used by end users such as hospitals, homecare settings, specialty clinics, and others.

The neurotrophic keratitis treatment market consists of revenues earned by entities by providing services such as ophthalmic evaluation, prescription of medications, corneal neurotization, customized treatment plans, counseling and support, tarsorrhaphy and antibiotic medication supplements. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurotrophic keratitis market also includes sales of artificial tears, recombinant human nerve growth factor eye drops, antibiotics and bandage contact lenses. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.